Owing to increasing occurrences of stress and depression, obesity, long working hours, and high incidences of diabetes, Japan’s market for sleep apnea diagnostic equipment is expected to reach $100 million in 2030, according to a forecast from GlobalData, a data and analytics company.

GlobalData’s report reveals that, in terms of value, Japan is the largest market for sleep apnea equipment in the Asia-Pacific region, accounting for around 45% of the market in 2023.

“It is crucial to acknowledge the rising prevalence of sleep disorders and their potential impact on health, as they may have extensive implications on the overall well-being. As awareness of this issue continues to rise, there is a clear need for advanced diagnostic and treatment solutions to enhance the quality of life for individuals,” says Rachna Tripathi, medical devices analyst at GlobalData, in a release. 

Shionogi, a research-driven pharmaceutical company based in Japan, and Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for obstructive sleep apnea (OSA) have recently collaborated to establish Shionogi-Apnimed Sleep Science with the primary goal of addressing the increasing impact of OSA on global public health. 

This collaboration signifies their shared commitment to expedite OSA solutions. The equally owned venture leverages the combined resources of both companies to effectively tackle sleep disorders, marking a significant step forward in improving the quality of life of individuals worldwide.

“A significant contribution to advances in this area is being made by increasing awareness of sleep apnea disorders, collaboration efforts of companies, and development of new technologies such as advanced wearables devices, personalized approach for treatment and integration of artificial intelligence,” says Tripathi in the release. 

Photo 6838463 © Norman Chan | Dreamstime.com